Hengrui Medicine
China's largest domestic innovative pharmaceutical company by R&D spend (~$1.5B USD annually, ~25% of revenue). Over 50 drugs in clinical development. Camrelizumab (PD-1 inhibitor) is its flagship. Aggressively out-licensing to western partners including deals with Merck and Elevar Therapeutics. Shanghai A-share listed only.
Therapeutic areas
Selected products and programs
Linked curated drug profiles
Selected active clinical trials
Phase 3 · Recruiting · Non-Small-Cell Lung Cancer
A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 MutationsPhase 3 · Recruiting · Non-Small Cell Lung Cancer With HER2- Mutations
Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJCPhase 3 · Recruiting · Gastric Cancer
SHR2554 Clinical Study of Chidamide in the Treatment of T-cell LymphomaPhase 3 · Recruiting · Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy
An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.Phase 3 · Recruiting · Advanced Gastroenteropancreatic Neuroendocrine Tumor
Safety and Efficacy of HRS-9190 Compared to Rocuronium for Tracheal Intubation and Bolus Maintenance in AdultsPhase 3 · Recruiting · Neuromuscular Blockade
Selected patent records
Primary and company sources
Company and pipeline information can change. Verify material decisions against the linked primary sources.
Evidence & limits
Source: Open the source record
- Record identifier
- /companies/hengrui-medicine/
- Event / action date
- Not separately retained
- Source update date
- Not separately retained
- Platform retrieval / processing date
- Not separately retained
What it supports. Connections found through the catalog, identifiers, or name and alias matching, with source links where retained.
Limits. A company association is not proof of ownership or sponsorship of every linked record. Product, substance, parent-company, and subsidiary relationships may differ.
Connection basis. Catalog, identifier, or normalized name association. Product and company connections are research leads, not ownership determinations.